Hyundai Bioscience Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 2,382.94 million compared to KRW 2,463.02 million a year ago. Net income was KRW 3,355.67 million compared to net loss of KRW 2,591.9 million a year ago. Basic earnings per share from continuing operations was KRW 85 compared to basic loss per share from continuing operations of KRW 71 a year ago. Diluted earnings per share from continuing operations was KRW 85 compared to diluted loss per share from continuing operations of KRW 71 a year ago. Basic earnings per share was KRW 85 compared to basic loss per share of KRW 53 a year ago.
For the nine months, sales was KRW 90.29 million compared to KRW 227.53 million a year ago. Net loss was KRW 4,661.33 million compared to KRW 6,537.93 million a year ago. Basic loss per share from continuing operations was KRW 119 compared to KRW 180 a year ago. Diluted loss per share from continuing operations was KRW 119 compared to KRW 180 a year ago. Basic loss per share was KRW 119 compared to KRW 108 a year ago.